Lab2Market: A novel strategy towards the computational development of peptide 'disruptors' to be used as molecular probes or therapeutic molecules.

通过Lab2Market合作伙伴计划，我们计划将能够快速筛选和开发新型肽治疗药物的软件推向市场。事实上，在药物输送的游戏中，领跑者包括小分子和大分子药物，但还有另一类介于两者之间的药物：肽。 自1921年推出用于治疗糖尿病的胰岛素肽以来，已有100多种肽类药物进入市场，用于治疗多种疾病，包括癌症、多发性硬化症、艾滋病毒感染和慢性疼痛（自2017年以来有10种肽类药物）。肽治疗剂的新市场增长导致超过150种肽处于临床开发中，另有超过600种肽正在进行临床前研究。该市场的增长速度超过任何其他治疗药物，估计每年超过400亿美元，与小分子药物相比，批准率翻了一番。为了直接应对生产新肽以实现市场增长的挑战，我们开发了TIPS（计算机肽合成器），这是一种用于开发肽基抑制剂的计算方法。这种计算管道有望减少时间和研究筛选成本，以有效地设计靶向特异性抑制剂。我们的目标是进行市场评估，以确定适当的策略，将我们的软件授权给主要的行业合作伙伴。

Through the Lab2Market partner program, we are proposing to bring to market software that enables rapid screening and development of novel peptide therapeutics. Indeed, the front runners in the game of drug delivery include small molecule and large molecule drugs, but there is another class that lands right in between; peptides. Since the introduction of insulin peptides for the treatment of diabetes in 1921, more than 100 peptide drugs have reached the market for a number of diseases, including cancer, multiple sclerosis, HIV infection, and chronic pain (10 peptides since 2017). New market growth into peptide therapeutics has resulted in >150 peptides in clinical development and another >600 peptides undergoing preclinical studies. The market is growing faster than any other therapeutics and is estimated at >$40 billion per year, with a double approval rate compared to small molecule drugs. To directly address challenges in generating new peptides to permit market growth, we have developed TIPS (The In silico Peptide Synthesizer), a computational method for developing peptide-based inhibitors. This computational pipeline promises to decrease the time and research screening costs to efficiently design target-specific inhibitors. Our objective is to carry out a Market Assessment to determine appropriate strategies to license our software to key industry partners.